Cerebrovascular disease (CVD) is the third most common cause of death worldwide and responsible for stroke and transient ischemic attack. This study aimed to investigate the clinical efficacy of high-dose lovastatin on patients with acute cerebral infarction. 150 patients with acute cerebral infarction were randomized divided into control group (n=50), 80 mg/d lovastatin (80 L) group (n=50) and 20 mg/d lovastatin (20 L) group (n=50). Control group, 80 L group and 20 L group received

more »

... treatment, conventional treatment together with lovastatin 80 mg/d and conventional treatment as well as lovastatin 20 mg/d respectively for 3 months. Biochemical indices, neurological deficit and plaque thickness and volume were assessed and recorded after treatment. After lovastatin treatment, the plasma levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) were significantly decreased in 80 L group and 20 L group, and highdensity lipoprotein (HDL) were significantly increased in 80 L group and 20 L group (p<0.05). Moreover, lovastatin could also decrease MMP-9 and hs-CRP levels (p<0.05). Furthermore, improved neurological deficit were found in lovastatin treatment groups. In addition, lovastatin treatment also improved plaque states include plaque thickness and volume in 80 L group and 20 L group (p<0.05). What's more, high-dose lovastatin a better ability in regulated plasma lipid levels, inflammation, neurological deficit and plaque thickness and volume than low-dose of lovastatin. Lovastatin could improve acute cerebral infarction and high-dose lovastatin treatment was better than low-dose lovastatin treatment. Guo X (2017) The effect of high-dose lovastatin therapy on patients with acute cerebral infarction Volume 2(2): 2-4 Guo X (2017) The effect of high-dose lovastatin therapy on patients with acute cerebral infarction Volume 2(2): 3-4 Guo X (2017) The effect of high-dose lovastatin therapy on patients with acute cerebral infarction Volume 2(2): 4-4